| Date | Time | Local Time | Room | Session | Role | Topic |
|---|---|---|---|---|---|---|
| 2022-09-16 | 15:30-15:42 | 2022-09-16,15:30-15:42 | Meeting Room 1 |
Oral Presentation 2 |
Speaker | 24-week combination treatment of TLR7 agonist TQ-A3334 and PD-L1 inhibitor TQ-B2450 enhanced HBsAg reduction in NAs-suppressed CHB patients: a preliminary analysis of a phase II study (OCEANcure05) |